MarketCap
Facebook
X
TelegramLuminex Corporation EBITDA | LMNX
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Luminex Corporation
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 72.9 M | -672 K | 36.5 M | 46 M | 31.5 M | 41.3 M | 33.9 M | 11.3 M | 27 M | 27.2 M |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 72.9 M | -672 K | 32.7 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical instruments industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BioLife Solutions
BLFS
|
-14.3 M | $ 38.61 | 3.51 % | $ 1.84 B |  USA |
 |
Harvard Bioscience
HBIO
|
-46.8 M | $ 8.32 | 1.09 % | $ 369 M | USA |
 |
ICU Medical
ICUI
|
244 M | $ 165.91 | -0.46 % | $ 4.09 B | USA |
 |
InfuSystem Holdings
INFU
|
25.2 M | $ 13.8 | -1.0 % | $ 285 M | USA |
 |
iRhythm Technologies
IRTC
|
-36.7 M | $ 121.86 | 0.49 % | $ 3.9 B | USA |
 |
Intuitive Surgical
ISRG
|
3.55 B | $ 451.72 | -0.13 % | $ 161 B | USA |
 |
LeMaitre Vascular
LMAT
|
78.3 M | $ 84.26 | -0.22 % | $ 1.91 B | USA |
 |
Nephros
NEPH
|
1.29 M | $ 3.6 | 1.98 % | $ 38.2 M | USA |
 |
Envista Holdings Corporation
NVST
|
332 M | $ 23.68 | 0.32 % | $ 3.98 B | USA |
 |
OraSure Technologies
OSUR
|
-61.8 M | $ 4.17 | 0.97 % | $ 306 M | USA |
 |
Pro-Dex
PDEX
|
14.4 M | $ 61.53 | -1.11 % | $ 198 B | USA |
 |
Pulse Biosciences
PLSE
|
-76.5 M | $ 52.77 | -0.47 % | $ 3.56 B | USA |
 |
Repligen Corporation
RGEN
|
134 M | $ 180.01 | 1.74 % | $ 10.1 M | USA |
 |
ResMed
RMD
|
2.09 B | $ 253.31 | 0.18 % | $ 36.9 B | USA |
 |
Retractable Technologies
RVP
|
-13.4 M | $ 0.58 | -0.02 % | $ 17.4 M | USA |
 |
STAAR Surgical Company
STAA
|
-83.4 M | $ 23.16 | 2.43 % | $ 1.15 B | USA |
 |
STERIS plc
STE
|
1.59 B | $ 229.89 | -0.97 % | $ 22.6 B | USA |
 |
Stereotaxis
STXS
|
-21.5 M | $ 0.99 | -2.99 % | $ 90 M | USA |
 |
Teleflex Incorporated
TFX
|
192 M | $ 137.03 | 0.54 % | $ 6.11 B | USA |
 |
Utah Medical Products
UTMD
|
12.2 M | $ 73.36 | -1.17 % | $ 238 M | USA |
 |
Atrion Corporation
ATRI
|
37.7 K | - | - | $ 810 M | USA |
 |
West Pharmaceutical Services
WST
|
756 M | $ 395.17 | 0.77 % | $ 28.6 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
-70 M | $ 9.22 | -2.28 % | $ 1.84 B | USA |
 |
NeuroMetrix
NURO
|
-8.69 M | - | 5.05 % | $ 9.02 M | USA |
 |
AngioDynamics
ANGO
|
-17 M | $ 12.17 | -1.62 % | $ 505 M | USA |
 |
Becton, Dickinson and Company
BDX
|
5.04 B | $ 195.87 | -1.37 % | $ 56.3 B | USA |
 |
The Cooper Companies
COO
|
1.06 B | $ 61.11 | -0.16 % | $ 12.2 B | USA |
 |
electroCore
ECOR
|
-12.7 M | $ 7.51 | 6.52 % | $ 63.7 K | USA |
 |
Glaukos Corporation
GKOS
|
-162 M | $ 178.61 | -0.15 % | $ 10.2 B | USA |
 |
Haemonetics Corporation
HAE
|
268 M | $ 119.33 | 0.69 % | $ 5.63 B | USA |
 |
Repro Med Systems
KRMD
|
-2.16 M | $ 3.13 | -1.26 % | $ 145 M | USA |
 |
Milestone Scientific
MLSS
|
-5.62 M | $ 0.31 | 1.02 % | $ 25.4 M | USA |
 |
Merit Medical Systems
MMSI
|
308 M | $ 94.16 | 0.92 % | $ 5.57 B | USA |
 |
Alcon
ALC
|
1.36 B | $ 70.0 | -0.24 % | $ 34.5 B |  Schweiz |
 |
CRH Medical Corporation
CRHM
|
33.9 M | - | - | $ 282 M | USA |
 |
AtriCure
ATRC
|
2.64 M | $ 61.13 | 3.66 % | $ 2.92 B | USA |
 |
Cantel Medical Corp.
CMD
|
123 M | - | -1.18 % | $ 3.4 B | USA |
 |
Baxter International
BAX
|
673 M | $ 25.28 | -0.08 % | $ 13 B | USA |
 |
Microbot Medical
MBOT
|
-14.7 M | $ 0.95 | -2.44 % | $ 43.5 M |  Israel |
 |
Akers Biosciences, Inc.
AKER
|
-12.3 M | - | -9.52 % | $ 20.6 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
16.2 M | - | - | $ 955 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
518 M | - | -0.05 % | $ 10.3 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
60 M | - | -0.02 % | $ 16.3 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
22.8 M | - | - | $ 28.6 M | USA |
 |
Isoray
ISR
|
-110 M | - | 0.03 % | $ 108 M | USA |
 |
Masimo Corporation
MASI
|
-164 M | - | - | $ 9.59 B | USA |
 |
Predictive Oncology
POAI
|
-181 M | - | - | $ 31.1 M | USA |